Oregon Public Employees Retirement Fund decreased its stake in Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) by 3.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 23,163 shares of the biopharmaceutical company’s stock after selling 780 shares during the period. Oregon Public Employees Retirement Fund’s holdings in Alexion Pharmaceuticals were worth $2,838,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. FMR LLC increased its stake in Alexion Pharmaceuticals by 12.0% in the second quarter. FMR LLC now owns 18,745,795 shares of the biopharmaceutical company’s stock valued at $2,188,759,000 after buying an additional 2,002,085 shares in the last quarter. Vanguard Group Inc. increased its stake in Alexion Pharmaceuticals by 1.6% in the second quarter. Vanguard Group Inc. now owns 13,478,718 shares of the biopharmaceutical company’s stock valued at $1,573,774,000 after buying an additional 216,269 shares in the last quarter. Ameriprise Financial Inc. increased its stake in Alexion Pharmaceuticals by 13.7% in the second quarter. Ameriprise Financial Inc. now owns 6,025,775 shares of the biopharmaceutical company’s stock valued at $703,575,000 after buying an additional 728,182 shares in the last quarter. BlackRock Institutional Trust Company N.A. increased its stake in Alexion Pharmaceuticals by 1.5% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 5,686,354 shares of the biopharmaceutical company’s stock valued at $663,939,000 after buying an additional 84,485 shares in the last quarter. Finally, BlackRock Fund Advisors increased its stake in Alexion Pharmaceuticals by 3.1% in the second quarter. BlackRock Fund Advisors now owns 4,564,948 shares of the biopharmaceutical company’s stock valued at $533,003,000 after buying an additional 135,363 shares in the last quarter. Institutional investors own 94.85% of the company’s stock.

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) traded down 2.39% during mid-day trading on Wednesday, hitting $122.59. 1,636,720 shares of the company were exchanged. The stock’s 50 day moving average is $122.56 and its 200-day moving average is $128.72. The company has a market cap of $27.48 billion, a price-to-earnings ratio of 74.75 and a beta of 1.45. Alexion Pharmaceuticals Inc. has a 12-month low of $110.56 and a 12-month high of $193.45.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, October 27th. The biopharmaceutical company reported $1.23 EPS for the quarter, beating the consensus estimate of $1.04 by $0.19. Alexion Pharmaceuticals had a return on equity of 10.58% and a net margin of 12.46%. The company had revenue of $799 million for the quarter, compared to the consensus estimate of $787.07 million. During the same quarter last year, the company posted $1.16 earnings per share. The company’s revenue for the quarter was up 19.9% compared to the same quarter last year. Equities research analysts predict that Alexion Pharmaceuticals Inc. will post $4.64 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Oregon Public Employees Retirement Fund Decreases Stake in Alexion Pharmaceuticals Inc. (ALXN)” was posted by Financial Market News and is the sole property of of Financial Market News. If you are accessing this report on another domain, it was stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this report can be accessed at http://www.financial-market-news.com/oregon-public-employees-retirement-fund-decreases-stake-in-alexion-pharmaceuticals-inc-alxn/1211284/.

Several research analysts have recently weighed in on the stock. Vetr upgraded shares of Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating and set a $107.00 target price for the company in a research note on Thursday, September 29th. Goldman Sachs Group Inc. upgraded shares of Alexion Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $158.00 target price for the company in a research note on Friday, October 28th. Piper Jaffray Cos. restated an “overweight” rating and issued a $185.00 target price on shares of Alexion Pharmaceuticals in a research note on Tuesday, August 16th. Barclays PLC upgraded shares of Alexion Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $150.00 to $155.00 in a research note on Tuesday. Finally, Credit Suisse Group AG restated a “buy” rating and issued a $165.00 target price on shares of Alexion Pharmaceuticals in a research note on Monday, November 7th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. Alexion Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $173.59.

In other news, SVP Edward Miller sold 367 shares of the firm’s stock in a transaction on Friday, September 9th. The shares were sold at an average price of $128.32, for a total value of $47,093.44. Following the sale, the senior vice president now owns 16,519 shares in the company, valued at $2,119,718.08. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Carsten Thiel sold 1,000 shares of the firm’s stock in a transaction on Tuesday, September 6th. The stock was sold at an average price of $125.94, for a total transaction of $125,940.00. Following the completion of the sale, the executive vice president now owns 40,579 shares in the company, valued at approximately $5,110,519.26. The disclosure for this sale can be found here. 4.41% of the stock is currently owned by insiders.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals Inc. (NASDAQ:ALXN).

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.